Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease
Amgad M. Rabie
Abstract
computational interpretation of the biological results supported that DDI strongly targets the key pocket of the SARS-CoV-2 RdRp main catalytic active site. The ideal pharmacophoric characteristics of the ligand DDI make it a typical inhibiting agent of SARS-CoV-2 multiplication processes (including high-fidelity proofreading), with its elastic structure open for many kinds of derivatization. In brief, the present results further uphold and propose the repurposing potentials of DDI against the different types of COVID-19 and convincingly motivate us to quickly launch its extensive preclinical/clinical pharmacological evaluations, hoping to combine it in the COVID-19 therapeutic protocols soon.
Topics & Concepts
VirologyDidanosineCoronavirusDrug repositioningBiologyViral replicationZalcitabineNucleoside analogueAntiviral drugDrugDrug discoveryPolymeraseNucleosideVirusPharmacologyMedicineEnzymeInfectious disease (medical specialty)Coronavirus disease 2019 (COVID-19)DiseaseZidovudineViral diseaseBioinformaticsBiochemistryPathologySARS-CoV-2 and COVID-19 ResearchCRISPR and Genetic EngineeringCytomegalovirus and herpesvirus research